Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
abemaciclib (verzenio) (1 trial)
cyclophosphamide (cytoxan) (6 trials)
docetaxel (taxotere) (4 trials)
epirubicin (ellence) (4 trials)
fluorouracil (efudex) (1 trial)
naltrexone (revia) (1 trial)
paclitaxel (taxol) (6 trials)
ribociclib (kisqali) (1 trial)
atezolizumab (Tecentriq) (1 trial)
bevacizumab (avastin) (1 trial)
carboplatin (paraplatin) (1 trial)
doxorubicin (Doxil) (2 trials)
fam-trastuzumab deruxtecan-nxki (Enhertu) (1 trial)
gemcitabine (gemzar) (1 trial)
ipatasertib (1 trial)
lapatinib (tykerb) (1 trial)
pembrolizumab (keytruda) (2 trials)
pertuzumab (perjeta) (2 trials)
sacituzumab govitecan (Trodelvy) (1 trial)
trastuzumab (herceptin) (5 trials)
trastuzumab emtansine (kadcyla) (1 trial)
Breast Neoplasms (Phase 3)
Carcinoma, Ductal (Phase 2)
Carcinoma, Ductal, Breast (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Trials (15 total)
Trial APIs (21 total)